Literature DB >> 25583716

The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.

Eleftheria Mavridou1, Joseph Meletiadis2, Antony Rijs3, Johan W Mouton3, Paul E Verweij3.   

Abstract

The majority of azole resistance mechanisms in Aspergillus fumigatus correspond to mutations in the cyp51A gene. As azoles are less effective against infections caused by multiply azole-resistant A. fumigatus isolates, new therapeutic options are warranted for treating these infections. We therefore investigated the in vitro combination of posaconazole (POSA) and caspofungin (CAS) against 20 wild-type and resistant A. fumigatus isolates with 10 different resistance mechanisms. Fungal growth was assessed with the XTT [2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt] method. Pharmacodynamic interactions were assessed with the fractional inhibitory concentration (FIC) index (FICi) on the basis of 10% (FICi-0), 25% (FICi-1), or 53 0% (FICi-2) growth, and FICs were correlated with POSA and CAS concentrations. Synergy and antagonism were concluded when the FICi values were statistically significantly (t test, P < 0.05) lower than 1 and higher than 1.25, respectively. Significant synergy was found for all isolates with mean FICi-0 values ranging from 0.28 to 0.75 (median, 0.46). Stronger synergistic interactions were found with FICi-1 (median, 0.18; range, 0.07 to 0.47) and FICi-2 (0.31; 0.07 to 0.6). The FICi-2 values of isolates with tandem-repeat-containing mutations or codon M220 were lower than those seen with the other isolates (P < 0.01). FIC-2 values were inversely correlated with POSA MICs (rs = -0.52, P = 0.0006) and linearly with the ratio of drug concentrations in combination over the MIC of POSA (rs = 0.76, P < 0.0001) and CAS (rs = 0.52, P = 0.0004). The synergistic effect of the combination of POSA and CAS (POSA/CAS) against A. fumigatus isolates depended on the underlying azole resistance mechanism. Moreover, the drug combination synergy was found to be increased against isolates with elevated POSA MICs compared to wild-type isolates.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583716      PMCID: PMC4325813          DOI: 10.1128/AAC.04469-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species.

Authors:  J Meletiadis; J W Mouton; J F Meis; B A Bouman; P J Donnelly; P E Verweij
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

Authors:  Adriana M Nascimento; Gustavo H Goldman; Steven Park; Salvatore A E Marras; Guillaume Delmas; Uma Oza; Karen Lolans; Michael N Dudley; Paul A Mann; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species.

Authors:  E Mellado; T M Diaz-Guerra; M Cuenca-Estrella; J L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

4.  Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus.

Authors:  Elias K Manavathu; George J Alangaden; Pranatharthi H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

5.  Azole-resistant central nervous system aspergillosis.

Authors:  Jan W M van der Linden; Rogier R Jansen; Dorine Bresters; Caroline E Visser; Suzanne E Geerlings; Ed J Kuijper; Willem J G Melchers; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

6.  Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.

Authors:  Nathan P Wiederhold; Dimitrios P Kontoyiannis; Jingduan Chi; Randall A Prince; Vincent H Tam; Russell E Lewis
Journal:  J Infect Dis       Date:  2004-09-10       Impact factor: 5.226

7.  Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Authors:  Paul A Mann; Raulo M Parmegiani; Shui-Qing Wei; Cara A Mendrick; Xin Li; David Loebenberg; Beth DiDomenico; Roberta S Hare; Scott S Walker; Paul M McNicholas
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.

Authors:  D T A Te Dorsthorst; P E Verweij; J F G M Meis; N C Punt; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs.

Authors:  E Mellado; G Garcia-Effron; L Alcazar-Fuoli; M Cuenca-Estrella; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.

Authors:  S L Kelly; D C Lamb; A J Corran; B C Baldwin; D E Kelly
Journal:  Biochem Biophys Res Commun       Date:  1995-02-27       Impact factor: 3.575

View more
  9 in total

Review 1.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  A Cationic Polymer That Shows High Antifungal Activity against Diverse Human Pathogens.

Authors:  Leslie A Rank; Naomi M Walsh; Runhui Liu; Fang Yun Lim; Jin Woo Bok; Mingwei Huang; Nancy P Keller; Samuel H Gellman; Christina M Hull
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Authors:  A Raffetin; V Courbin; V Jullien; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

4.  Heterogeneity in the transcriptional response of the human pathogen Aspergillus fumigatus to the antifungal agent caspofungin.

Authors:  Ana Cristina Colabardini; Fang Wang; Zhiqiang Dong; Lakhansing Pardeshi; Marina Campos Rocha; Jonas Henrique Costa; Thaila Fernanda Dos Reis; Alec Brown; Qais Z Jaber; Micha Fridman; Taicia Fill; Antonis Rokas; Iran Malavazi; Koon Ho Wong; Gustavo Henrique Goldman
Journal:  Genetics       Date:  2022-01-04       Impact factor: 4.402

5.  Cell-Cycle-Associated Expression Patterns Predict Gene Function in Mycobacteria.

Authors:  Aditya C Bandekar; Sishir Subedi; Thomas R Ioerger; Christopher M Sassetti
Journal:  Curr Biol       Date:  2020-09-10       Impact factor: 10.834

6.  Dirhamnolipids secreted from Pseudomonas aeruginosa modify anjpegungal susceptibility of Aspergillus fumigatus by inhibiting β1,3 glucan synthase activity.

Authors:  Benoit Briard; Vero Rasoldier; Perrine Bomme; Noureddine ElAouad; Catherine Guerreiro; Pierre Chassagne; Laetitia Muszkieta; Jean-Paul Latgé; Laurence Mulard; Anne Beauvais
Journal:  ISME J       Date:  2017-03-24       Impact factor: 10.302

7.  cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex.

Authors:  Vanessa R Barrs; Jos Houbraken; Jessica J Talbot; Jens C Frisvad; Jacques F Meis; Ferry Hagen; Paul E Verweij; David E Hibbs; Felcia Lai; Paul W Groundwater; Robert A Samson; Sarah E Kidd
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 8.  Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.

Authors:  Aidan Kane; Dee A Carter
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-14

9.  In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.

Authors:  J B Buil; R J M Brüggemann; L Bedin Denardi; W J G Melchers; P E Verweij
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.